Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

With JBCHEPHARM's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.000000
forwardPE 33.465603
debtToEquity 1.075000
earningsGrowth 0.216000
revenueGrowth 0.105000
grossMargins 0.670510
operatingMargins 0.235240
trailingEps 47.410000
forwardEps 59.771820

JBCHEPHARM's positive earnings and revenue growth suggest the company is on a path to business expansion. This upward trend signals strong financial health, indicating that JBCHEPHARM is well-positioned for sustained growth in both profits and revenue.
JBCHEPHARM's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
JBCHEPHARM's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that JBCHEPHARM's financial performance will improve in the current financial year.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

The stock price of JBCHEPHARM has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


JBCHEPHARM had 60 sell transactions, while the market price was at 1718.736669921875 per share.3 separate transactions to buy JBCHEPHARM were completed, while market price hovered around 1875.4333089192708.The recent buying activity at current J. B. Chemicals & Pharmaceuticals Limited price levels exceeds selling, suggesting a potential positive outlook. Investors may see this trend as an indicator that the stock is likely to perform well, reflecting growing confidence.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


JBCHEPHARM has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view JBCHEPHARM as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.